Skip to main content
Equibles
SPRY logo

SPRY · ARS Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio

Track SPRY — free

Use SPRY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SPRY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.01 -0.03 (-0.62%)
Russell 2000 member Rebalance outlook locked
Market Cap
$397.79M
Shares
99.45M
Volume · Oct 26 557.86K Avg daily vol (3M) 1.74M

ARS Pharmaceuticals, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for ARS Pharmaceuticals, Inc. (SPRY), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q2
2026-08-13
ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call Transcript
Positive tone Strategic shift to provider-focused commercial execution NEPI market share performance Cost discipline and path to profitability
Revenue
$33.66M
▲ 114.2% YoY
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-15
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call
Revenue
$22.68M
▲ 184.5% YoY
Diluted EPS
$-0.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-09
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
Positive tone Neffy clinical profile and real-world data Direct-to-consumer campaign and patient engagement Payer access and prior authorization
Revenue
$28.09M*
▼ 67.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript
Confident tone U.S. neffy revenue growth International expansion Get neffy On Us virtual prescribing program
Revenue
$32.50M
▲ 1471.6% YoY
Diluted EPS
$-0.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
Confident tone neffy U.S. commercial momentum and revenue growth Payer access and prior authorization progress DTC advertising campaign
Revenue
$15.72M
▲ 3043.4% YoY
Diluted EPS
$-0.46
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript
Confident tone neffy Commercial Launch and Revenue Growth neffy Experience Program and Physician Adoption Pediatric Dose (1 mg) Approval
Revenue
$7.97M
Diluted EPS
$-0.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Call Transcript
Confident tone neffy launch trajectory Payer coverage and prior authorization Pediatric label expansion
Revenue
$86.58M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript
Confident tone neffy U.S. launch progress Physician adoption and education International partnerships and licensing
Revenue
$2.07M
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-09
ARS Pharmaceuticals, Inc. (SPRY) Q2 2024 Earnings Call
Revenue
$500,000
▲ 4900% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
ARS Pharmaceuticals, Inc. (SPRY) Q4 2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–10 of 10 webcasts
Key facts CIK 1671858 CUSIP 82835W108 13F (30d) 21 filings 21 filers Visit website Investor relations